Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 8/20 | 0.51 |
| ▸ | MTOR | P42345 | 3/20 | 0.51 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6726818 | 0.87 | PIK3CA (0.49) | PIK3CAMTORCRHR1RAB9ANPC1 | |
| SCHEMBL1552152 | 0.85 | PIK3CA (0.69) | PIK3CAMTORCRHR1RAB9ANPC1 | |
| SCHEMBL6726840 | 0.84 | PIK3CA (0.55) | PIK3CAMTORCRHR1RAB9ANPC1 | |
| SCHEMBL6726845 | 0.84 | PIK3CA (0.53) | PIK3CAMTORCRHR1RAB9ANPC1 | |
| SCHEMBL6726842 | 0.82 | PIK3CA (0.55) | PIK3CAMTORCRHR1RAB9ANPC1 | |
| SCHEMBL6726829 | 0.81 | PIK3CA (0.51) | PIK3CAMTORCRHR1RAB9ANPC1 | |
| SCHEMBL6726849 | 0.80 | PIK3CA (0.51) | PIK3CAMTORCRHR1RAB9ANPC1 | |
| SCHEMBL6726920 | 0.80 | PIK3CA (0.49) | PIK3CAMTORCRHR1RAB9ANPC1 | |
| SCHEMBL6726831 | 0.79 | PIK3CA (0.57) | PIK3CAMTORCRHR1RAB9ANPC1 | |
| SCHEMBL11902424 | 0.78 | CRHR1 (0.46) | PIK3CAMTORCRHR1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130217689-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-8440664-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120202812-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8183240-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100075951-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075951-A1 | Heteroaryls and uses thereof | PIK3R3, AKT1S1, PIK3R1 | PIK3CA 11/4885MTOR 148/4885CRHR1 1644/4885 |
| US-20130217689-A1 | HETEROARYLS AND USES THEREOF | PIK3R3, AKT1S1, PIK3R1 | PIK3CA 11/4885MTOR 148/4885CRHR1 1644/4885 |
| US-20120202812-A1 | HETEROARYLS AND USES THEREOF | PIK3R3, AKT1S1, PIK3R1 | PIK3CA 11/4885MTOR 148/4885CRHR1 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.